Taiwan’s biotech industry is experiencing a surge in global orders due to the “China+1” strategy, where companies diversify supply chains away from sole reliance on China. This trend, coupled with the global race in artificial intelligence, is creating a dual-engine growth opportunity for Taiwanese manufacturers. Companies are capitalizing on their strengths in niche areas and benefiting from increased demand as international firms seek alternative production hubs. Taiwan's established biotech sector and manufacturing capabilities position it as a favorable destination for these diversifying businesses. This shift demonstrates Taiwan's resilience and ability to adapt to changing global economic conditions. The strategy is bolstering Taiwan’s position as a key player in the global biotech supply chain, offering stability and innovation. Industry analysts predict continued growth as the “China+1” approach becomes more widespread.